AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 4.35 |
Market Cap | 255.97M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.29 |
PE Ratio (ttm) | -15.14 |
Forward PE | n/a |
Analyst | Buy |
Ask | 5.02 |
Volume | 406,194 |
Avg. Volume (20D) | 611,600 |
Open | 4.55 |
Previous Close | 4.53 |
Day's Range | 4.35 - 4.55 |
52-Week Range | 3.46 - 6.75 |
Beta | undefined |
About VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatr...
Analyst Forecast
According to 2 analyst ratings, the average rating for VNDA stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 253.08% from the latest price.
Next Earnings Release
Analysts project revenue of $51.25M, reflecting a 13.21% YoY growth and earnings per share of -0.17, making a 325.00% increase YoY.
3 weeks ago · seekingalpha.com
Vanda Pharmaceuticals: Net-Net Status Presents A Trading OpportunityVanda Pharmaceuticals has returned to net-net status. Vanda has been building out their sales team to ramp up Fanapt and PONVORY distribution. I'm interested in buying the stock prior to FY 2024 resul...